about
Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer.Comparison of the effectiveness of erlotinib, gefitinib, and afatinib for treatment of non-small cell lung cancer in patients with common and rare EGFR gene mutations.Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.The efficacy of EGFR gene mutation testing in various samples from non-small cell lung cancer patients: a multicenter retrospective study.The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer.Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.Analysis of treatment results in primary germ cell tumours with mediastinal location: own experience.Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.Evaluation of antitumor activity using change in tumor size of the survivin antisense oligonucleotide LY2181308 in combination with docetaxel for second-line treatment of patients with non-small-cell lung cancer: a randomized open-label phase II stuA decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.Evaluation of miR-506 and miR-4316 expression in early and non-invasive diagnosis of colorectal cancer.Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: results of a randomized phase II study.Prognostic value of synaptophysin and chromogranin a expression in patients receiving palliative chemotherapy for advanced non-small-cell lung cancer.Application of plasma circulating microRNA-448, 506, 4316, and 4478 analysis for non-invasive diagnosis of lung cancer.DISRUPT: a randomised phase 2 trial of ombrabulin (AVE8062) plus a taxane-platinum regimen as first-line therapy for metastatic non-small cell lung cancer.Two neoplasms rich in small lymphocytes, B1B2 thymoma and small lymphocytic lymphoma, intermingled in one tumor mass. A case report.Plasma circulating microRNA-944 and microRNA-3662 as potential histologic type-specific early lung cancer biomarkers.[The role of systemic therapies of non-small cell lung cancer and malignant pleural mesothelioma: updated expert recommendations].The applicability of a predictive index for second- and third-line treatment of unselected non-small-cell lung cancer patients.Phase III safety study of intravenous NEPA: a novel fixed antiemetic combination of fosnetupitant and palonosetron in patients receiving highly emetogenic chemotherapyPreventing central nervous system metastases in non-small cell lung cancerThe qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factorsPrognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: external validation in a phase III trial comparing vinflunine with docetaxelCorrelation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patientsConsensus statement on a screening programme for the detection of early lung cancer in PolandUpdated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
P50
Q33683680-A8CA1D0C-0871-452A-95AC-9B3DBA27BA82Q33751194-D2058189-40AF-4B5A-871A-185CCBD8BC35Q34491507-6DF6B149-5708-4D8A-A959-870F7C96E1E9Q34809526-583077E7-7257-41B5-9D3A-DA8CC0AF4751Q36378565-530FA8E8-83D7-44A0-9C70-6294EDEAED28Q36942619-40A801C8-0170-495A-A01D-94F7679EA27FQ37539257-966B869D-7D60-4872-AABC-7C84AEFCACC2Q38194931-12637AAF-2257-4D18-9480-CA1047111982Q38669328-3DDCFE2C-31C1-4EEE-A811-0F137C5B2EEBQ39092253-E5C05C5B-359B-4108-A1C0-9D75A42D2370Q39428802-DC1A69B9-E767-4327-A041-F20EE97265FCQ40408396-DD92AFCE-8E7D-453C-8AB1-E11018BA9FAEQ41030204-E71F7C88-BCC2-4971-8778-F59FDD240F8DQ42997441-C0D1429E-DEBE-4EAE-BF1D-8C756140D4FBQ47947285-8CA1AFEE-26F9-4EA4-926D-D0B151DF28EFQ51597823-8D8BD513-FD3E-4A62-B22C-148BDEB3F4FAQ52650698-4C0EEFDB-BA43-4F3F-A447-F63305393D83Q52865197-468E8938-3D44-4AA2-85C5-4B19FF1FC2CAQ53466708-BA5E5BAB-846E-409E-91B8-401D3DEB24B5Q54369715-6137F9C0-43E0-4201-B46A-E08ABD86FEEDQ54619423-D6A9E7BF-4466-4329-B876-C7BE28FE72B4Q56517642-D59E81F7-2B37-4137-8EBF-D71818B0237AQ57129460-92034118-7AFA-4864-A322-452F70FEFBC3Q83457600-3CB83A8D-D893-4ED3-B7C8-D3072EFFDB22Q83504223-29753693-E6AC-4EED-BCED-71AB8F9B64A4Q85359341-813790B9-2B00-4161-BF72-E1D317F9715DQ87910604-4F3F4416-CBE7-481A-9F0C-ADDBCA0AE786Q88734999-DE1BA3E9-CD55-4A0D-8394-9E066347F2DE
P50
description
researcher ORCID ID = 0000-0002-9452-3229
@en
wetenschapper
@nl
name
Dariusz M Kowalski
@ast
Dariusz M Kowalski
@en
Dariusz M Kowalski
@es
Dariusz M Kowalski
@nl
type
label
Dariusz M Kowalski
@ast
Dariusz M Kowalski
@en
Dariusz M Kowalski
@es
Dariusz M Kowalski
@nl
prefLabel
Dariusz M Kowalski
@ast
Dariusz M Kowalski
@en
Dariusz M Kowalski
@es
Dariusz M Kowalski
@nl
P106
P1153
16686795600
P31
P496
0000-0002-9452-3229